The current status of antimicrobial resistance of <i>Streptococcus pneumoniae</i> and specific vaccine prevention of pneumococcal infection

Abstract

The constant increase in the level of resistance of Streptococcus pneumoniae to antimicrobial drugs significantly affects the algorithms for the pharmacotherapy of pneumococcal infection, reduces the effectiveness of the therapy and increases the healthcare costs. In this regard, specific vaccine prevention of pneumococcal diseases is a socially significant and economically promising and profitable area. The aim of the study is to analyze the current status of antimicrobial resistance of S. pneumoniae in healthy carriers and patients with non-invasive and invasive pneumococcal infections, as well as specific vaccine prevention of pneumococcal infection. Conclusion. An increase in the number of pneumococcal strains resistant to macrolides and tetracycline has been noted, as well as a trend toward an increase in resistance to beta-lactam antibiotics. Given the spread of resistant strains of S. pneumoniae, a continuous epidemiological surveillance of pneumococcal infection with an assessment of the dynamics of pneumococcal serotype resistance and the effectiveness of vaccination is needed on a global scale.